Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
12.35
+0.24 (1.98%)
Mar 31, 2025, 1:31 PM EDT - Market open
Mesoblast Employees
Mesoblast had 73 employees as of June 30, 2024. The number of employees decreased by 10 or -12.05% compared to the previous year.
Employees
73
Change (1Y)
-10
Growth (1Y)
-12.05%
Revenue / Employee
$77,671
Profits / Employee
-$1,415,767
Market Cap
1.57B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MESO News
- 17 hours ago - First Three Children to Commence Treatment With Ryoncil® - GlobeNewsWire
- 4 days ago - Ryoncil® is Now Available for Purchase in the United States - GlobeNewsWire
- 17 days ago - Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States - GlobeNewsWire
- 19 days ago - Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall - GlobeNewsWire
- 4 weeks ago - Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter - GlobeNewsWire
- 4 weeks ago - Mesoblast Financial Results and Corporate Update Webcast - GlobeNewsWire
- 5 weeks ago - Dr. Gregory George MD PhD Joins Mesoblast Board - GlobeNewsWire